Welcome to our dedicated page for Pharma-Bio Serv SEC filings (Ticker: PBSV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Pharma-Bio Serv’s filings usually starts with one question: where does its revenue really come from? Whether you need to confirm how many top pharmaceutical clients drive sales, or you want to track Form 4 insider moves before the next contract win, this page gives you the answers in one place.
Scroll straight to the documents investors ask for most—each labeled and timestamped the moment EDGAR releases them. Our AI-powered summaries turn a 200-page Pharma-Bio Serv annual report 10-K simplified into clear bullet points that flag client concentration, FDA compliance risks, and segment margins. Click a Pharma-Bio Serv quarterly earnings report 10-Q filing and see revenue shifts by geography without hunting through footnotes.
Need real-time alerts? Set notifications for a Pharma-Bio Serv 8-K material events explained the minute management announces a new validation contract, or follow Pharma-Bio Serv Form 4 insider transactions real-time to monitor executive stock transactions. Stock Titan’s AI also decodes the Pharma-Bio Serv proxy statement executive compensation so you can understand pay structures tied to FDA audit milestones.
- Instant access to every filing type—10-K, 10-Q, 8-K, S-8, and more
- AI summaries that answer “What changed since last quarter?” in seconds
From Pharma-Bio Serv insider trading Form 4 transactions to detailed risk factor shifts, our platform keeps analysts, portfolio managers, and compliance teams ahead of the curve. If you’re understanding Pharma-Bio Serv SEC documents with AI for the first time or need a quick Pharma-Bio Serv earnings report filing analysis, it’s all here—explained simply and updated in real time.
Pharma-Bio Serv, Inc. (PBSV) discloses share counts, tax items, repurchases and customer concentration. The company reports 10,000,000 authorized shares with 23,519,672 issued and 22,920,442 outstanding at July 31, 2025, and notes 599,230 common shares held in treasury at that date. Under U.S. tax reforms, a 100% exemption on certain foreign-source dividends is noted while GILTI subjects foreign subsidiary earnings to a reduced U.S. tax rate of 10.5%. The Transition Tax payment period runs eight years through the companys second quarter of fiscal 2026. The Spanish subsidiary tax rate is 25%. During the period, the company repurchased 536,258 and 498,557 common shares for aggregate amounts of $507,112 and $484,871, respectively, and paid $1,719,918 on March 20, 2025. Revenue concentration from certain global affiliated groups rose to 53.8% for the nine months ended July 31, 2025, and amounts due from those affiliates represented 55.3% of total accounts receivable at July 31, 2025.
FAQ
What is the current stock price of Pharma-Bio Serv (PBSV)?
What is the market cap of Pharma-Bio Serv (PBSV)?
